16 August 2022
RUA Life Sciences plc
("RUA", the "Company" or the "Group")
Result of AGM
RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:
| Res No. | Votes For | % | Votes Against | % | Votes Total | % I.S.C. | Votes Withheld |
| 01 | 2,517,502 | 100.00% | 0 | 0.00% | 2,517,502 | 11.35 | 11,763 |
| 02 | 1,164,389 | 96.51% | 42,142 | 3.49% | 1,206,531 | 5.44 | 1,322,734 |
| 03 | 2,517,502 | 100.00% | 0 | 0.00% | 2,517,502 | 11.35 | 11,763 |
| 04 | 2,517,502 | 100.00% | 0 | 0.00% | 2,517,502 | 11.35 | 11,763 |
| 05 | 1,900,843 | 94.80% | 104,178 | 5.20% | 2,005,021 | 9.04 | 524,244 |
| 06 | 2,413,324 | 95.86% | 104,178 | 4.14% | 2,517,502 | 11.35 | 11,763 |
| 07 | 2,517,487 | 100.00% | 15 | 0.00% | 2,517,502 | 11.35 | 11,763 |
| 08 | 2,508,972 | 99.66% | 8,530 | 0.34% | 2,517,502 | 11.35 | 11,763 |
| 09 | 2,404,481 | 95.51% | 112,921 | 4.49% | 2,517,402 | 11.35 | 11,863 |
| 10 | 2,404,385 | 95.51% | 112,921 | 4.49% | 2,517,306 | 11.35 | 11,959 |
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Dr Caroline Stretton, Group MD Tel: +44 (0)1294 317073
Cenkos Securities plc (Nominated Adviser and Broker) Tel: +44 (0)20 7397 8900
Giles Balleny/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-EonTM, manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
| RUA Medical: | End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
|
| RUA Biomaterials: | Licensor of Elast-EonTM polymers to the medical device industry.
|
| RUA Vascular: | Commercialisation of open surgical vascular grafts and patches
|
| RUA Structural Heart: | Development of polymeric leaflet systems for heart valves. |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
